



FOR IMMEDIATE RELEASE

August 12, 2019

Contact: Jacqueline Clark, [jacqueline@sqcomms.com](mailto:jacqueline@sqcomms.com)

Charlie Patterson, [charlie@sqcomms.com](mailto:charlie@sqcomms.com)

### **3 Years and Still No License: DEA Registrant Biopharmaceutical Research Company Still Awaiting Authorization to Cultivate Cannabis for Research**

**MONTEREY, CA** - On August 12, 2016, the Drug Enforcement Administration (DEA) promised to open up a licensing process for American entities seeking to cultivate cannabis for scientific research purposes. Biopharmaceutical Research Company (BRC) is one of 25+ applicants who applied for a license back in 2016. Today, on the third anniversary of the DEA accepting applications for cultivation for research, the DEA still has yet to process BRC's application, or any of the other 25 applications it received for this program.

"Our company applied for DEA authorization to cultivate cannabis because I wanted to explore the promise that cannabis could provide my fellow veterans with help to manage their chronic pain, depression, post-traumatic stress and other wartime wounds, but we've been waiting ever since," said George Hodgkin, a former Navy SEAL and founder and CEO of BRC.

In its effort to obtain DEA authorization, BRC has built a DEA-compliant facility, hired expert scientists, researchers and consultants, and painstakingly adhered to the letter of the law in the application process.

"In its refusal to process BRC's and others' applications, the DEA and the Department of Justice (DOJ) are delaying legitimate research that will help health care providers better understand the medicinal value of cannabis, as well as provide government authorities with the knowledge necessary to effectively regulate it," Hodgkin continued. "There is bipartisan support in Congress for cannabis research. It is time for the DEA to heed the will of Congress - and the will of patients and health care providers across the country - and process our applications for cannabis cultivation and research. We should be leading the world in the creation of intellectual property and American jobs, but sadly these bureaucratic delays are sending American dollars overseas."

**About Biopharmaceutical Research Company**

BRC currently holds a DEA Registration and is working with the DEA for approval to manufacture clean, consistent and compliant cannabis for federally approved researchers around the world. BRC also conducts federally compliant cannabis-specific analytical activities.

George Hodgins is a graduate of the Stanford Graduate School of Business, a former Navy SEAL and the CEO of Biopharmaceutical Research Company near Monterey, CA. To learn more about BRC's work, visit <https://www.biopharmaresearchco.com/>.

###